
Sign up to save your podcasts
Or


Interview with Naiyer A. Rizvi, MD, author of Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
By JAMA Network3.8
1111 ratings
Interview with Naiyer A. Rizvi, MD, author of Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

320 Listeners

496 Listeners

40 Listeners

163 Listeners

57 Listeners

112,586 Listeners

38 Listeners

56,435 Listeners

21 Listeners

12 Listeners

8 Listeners

16 Listeners

18 Listeners

5 Listeners

6 Listeners

44 Listeners

29 Listeners

9 Listeners

90 Listeners

14 Listeners

5 Listeners

5 Listeners

106 Listeners

19 Listeners

14,589 Listeners

3 Listeners

1,227 Listeners